Biobetters, more than biosimilars, are the big opportunity for biopharm and CROs hoping to profit from biologics patent expirations, say experts.

via Biobetters a big opportunity for biopharm and CROs.

I am not sure if I will agree with the authro here. A biobetter is going to require a lot more clinical testing (maybe even phase 3) to prove it is really “better”. So, i don’t think a lot of pharma are going to jump at it like biosimilar which, most likely requre a lot less clinical test. So, i just don’t think there is going to be enough incentive for pharma to make biobetter a main stream.